Methylbenzodioxolylbutanamine

Methylbenzodioxolylbutanamine (MBDB; Eden; Methyl-J; 1,3-Benzodioxolyl-N-methylbutanamine) is a psychoactive drug and member of the phenethylamine chemical class which acts as an entactogen, psychedelic, and stimulant. It is closely related to MDMA in terms of chemical structure and effects.

Chemistry

MBDB is a substituted phenethylamine with a phenyl ring bound to an amino (NH2) group through an ethyl chain. It is structurally related to methamphetamine, differing by the presence of a methylenedioxy functional group and a methyl group on the alpha carbon.

Pharmacology

MBDB's effects are mediated by its activity at the serotonin and norepinephrine receptors. It is thought to work primarily as a serotonin-norepinephrine-dopamine releasing agent (SNDRA), promoting the release of these neurotransmitters in the brain. This leads to increased activity of these neurotransmitter systems, producing the characteristic effects of the drug.

Effects

The effects of MBDB are similar to those of MDMA, but are generally less intense and longer-lasting. Users often report feelings of euphoria, increased empathy, and heightened sensory perception. However, MBDB is also associated with a number of negative effects, including anxiety, paranoia, and potential neurotoxicity.

Legal Status

MBDB is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act. In the United Kingdom, it is a Class A drug under the Misuse of Drugs Act.

See Also

• MDMA
• Methamphetamine
• Psychoactive drug
• Phenethylamine